Get started
Author

Marcin Puto

Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy
2016 · S Vasu, H Wu, et al. · Bone Marrow Transplantation · 68
Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience
2019 · Filiz Yucebay, Christina Matthews, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 21
Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
2021 · Nidhi Sharma, Qiuhong Zhao, et al. · Cancers · 20
PDF
Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
2021 · Delaney Wolfe, Qiuhong Zhao, et al. · Cancers · 19
PDF
Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
2022 · Sumithira Vasu, Matthew Bostic, et al. · Blood Advances · 18
PDF
Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
2020 · Allison Grana, Natalia Gut, et al. · Clinical Lymphoma Myeloma & Leukemia · 12
Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center
2023 · Tracelyn Freeman, Kiersten Williams, et al. · World Journal of Oncology · 10
PDF
Analysis of VDT-PACE Utilization in Multiple Myeloma Patients Treated at MSKCC for Relapsed Disease or Cytoreduction and Stem Cell Mobilization after Initial Induction Therapy
2014 · Kristen Beyer, Samuel Rosner, et al. · Blood · 9
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS
2020 · Brendan Rasor, Tyler Dickerson, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 7
Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)
2021 · Joseph Maakaron, Qiuhong Zhao, et al. · Blood · 2
Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)
2019 · Joseph Maakaron, Qiuhong Zhao, et al. · Blood · 2
Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?
2018 · John L. Vaughn, Qiuhong Zhao, et al. · Bone Marrow Transplantation · 2
Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity
2017 · Sarah Wall, Qiuhong Zhao, et al. · Blood · 2
Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma
2026 · Joseph E. Maakaron, Qiuhong Zhao, et al. · Transplantation and Cellular Therapy · 1
Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial
2021 · Chitra Hosing, Zachary Braunstein, et al. · Blood · 1
Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease.
2021 · Delaney Wolfe, Qiuhong Zhao, et al. · Journal of Clinical Oncology · 1
Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS
2019 · Brendan Rasor, Tyler Dickerson, et al. · Blood · 1
Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Adding Steam to ASCT
2021 · Joseph Maakaron, Qiuhong Zhao, et al. · Transplantation and Cellular Therapy
Maintenance Romidepsin (Rom) after Allogeneic Stem Cell Transplantation (Allo-SCT) in Aggressive T-Cell Malignancies Induces Long-Term Remissions and Enhances NK-Cell Cytotoxicity
2021 · Alaa Ali, Chitra Hosing, et al. · Transplantation and Cellular Therapy
Impact of Opioid Use after Blood and Marrow Transplantation (BMT): A Single-Center Analysis
2021 · Noha Soror, Ashleigh Keiter, et al. · Transplantation and Cellular Therapy
Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS
2020 · Brendan Rasor, Tyler Dickerson, et al. · Transplantation and Cellular Therapy
Phase I Dose‐escalation Study of Venetoclax Plus Beam Followed by Autologous Stem Cell Transplant (asct) for Chemoresistant, Relapsed/refractory, or High‐risk Non‐hodgkin's Lymphoma (nhl); Preliminary Results
2019 · J. Maakaron, Q. Zhao, et al. · Hematological Oncology
Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation
2018 · Caner Saygin, John L Vaughn, et al. · Blood
Development of a Transition of Care Medication Education Program for Hematopoietic Stem-Cell Transplantation Patients
2016 · Julianna Roddy, Marcin Puto, et al. · Transplantation and Cellular Therapy
PDF
Risk of Nausea and Vomiting in Patients with Lymphoma Undergoing High Dose Therapy with Autologous Stem Cell Rescue
2012 · M. Puto, N. Adel, et al. · Transplantation and Cellular Therapy
PDF
Works count: 26
Citation count: 196
H-index: 8
I10-index: 7
Year
Topic
Type